Table 5.
Characteristics of the 38 DF patients with imatinib treatment stratified by HI proportion.
| HI on T1 CE <75% (n = 11) | HI on T1 CE≥75%(n = 27) | P | ||
|---|---|---|---|---|
| Size (mm) | 1–49 | 4 | 6 | 0.43 |
| ≥50 | 7 | 21 | ||
| Tumor volume (mm3) | 1–96,590 ≥96,590 |
6 5 |
12 15 |
0.57 |
| Age (years) | 1–29 | 8 | 10 | 0.04* |
| ≥50 | 3 | 17 | ||
| Sex | Male | 5 | 7 | 0.27 |
| Female | 6 | 20 | ||
| Dominant shape | Round/oval | 1 | 6 | 0.09 |
| Lobulated | 7 | 7 | ||
| Infiltrative | 3 | 14 | ||
| Multifocality | No | 8 | 20 | 1.00 |
| Yes | 3 | 7 | ||
| Adjacent structure involvement | None | 1 | 9 | 0.13 |
| Adjacent | 4 | 5 | ||
| Encased | 3 | 11 | ||
| Invaded | 3 | 2 | ||
| Compartment of origin | Deep fascial/intermuscular | 7 | 20 | 0.69 |
| Intramuscular | 3 | 5 | ||
| Superficial fascial | 1 | 1 | ||
| Subcutaneous | 0 | 1 | ||
| Dose escalation | No | 6 | 13 | 0.72 |
| Yes | 5 | 14 | ||
| History of treatment | Primary | 2 | 5 | 0.23 |
| Recurrence with previous surgery | 7 | 10 | ||
| Recurrence with previous medical therapy | 2 | 8 | ||
| Recurrence with previous surgery and radiation/RFA | 0 | 4 |
*P < 0.05; HI, hyperintense proportion; CE, contrast enhancement.